<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260113</url>
  </required_header>
  <id_info>
    <org_study_id>CSSG-06</org_study_id>
    <nct_id>NCT04260113</nct_id>
  </id_info>
  <brief_title>Apatinib for Inoperable Advanced Chondrosarcoma</brief_title>
  <acronym>AIAC</acronym>
  <official_title>The Effectivity and Toxicity of Apatinib for Unresectable Advanced Chondrosarcoma: a Multicentric Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising
      effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after
      failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which
      specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University
      affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated
      chondrosarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>from initial treatment to date of recorded progression or death or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>from initial treatment to death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>CR+PR according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate</measure>
    <time_frame>6 months</time_frame>
    <description>CR+PR+SD according to RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Efficacy</condition>
  <condition>Toxicity, Drug</condition>
  <arm_group>
    <arm_group_label>Apatinib Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib orally 500mg once daily half an hour after meal</description>
    <arm_group_label>Apatinib Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) histologically confirmed high-grade sarcoma;

          -  2) initial treatment in the orthopedic oncology departments of the two affiliated
             hospitals of Peking University;

          -  3) tumors not amenable to curative treatment or inclusion in clinical trials;

          -  4) unresectable local advanced lesions or multiple metastatic lesions that could not
             be cured by local therapy;

          -  5) measurable lesions according to Response Evaluation Criteria for Solid Tumors
             (RECIST1.1) ;

          -  6) Eastern Cooperative Oncology Group performance status 0 or 1;

          -  7) acceptable hematologic, hepatic, and renal function.

        Exclusion Criteria:

          -  had central nervous system metastasis;

          -  had other kinds of malignant tumors at the same time; had cardiac insufficiency or
             arrhythmia;

          -  had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine
             protein â‰¥ ++ and so on;

          -  had pleural or peritoneal effusion that needs to be handled by surgical treatment;

          -  combined with other infections or wounds;

          -  pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Musculoskeletal Tumor Center of Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Univresity Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China. BMC Cancer. 2018 Apr 6;18(1):396. doi: 10.1186/s12885-018-4303-z.</citation>
    <PMID>29625604</PMID>
  </reference>
  <reference>
    <citation>Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist. 2019 Jul;24(7):e542-e550. doi: 10.1634/theoncologist.2018-0542. Epub 2018 Dec 17.</citation>
    <PMID>30559126</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrosarcoma</keyword>
  <keyword>apatinib</keyword>
  <keyword>inoperable</keyword>
  <keyword>toxicity</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

